Study to Evaluate Response Rates in CHC [chronic hepatitis C] Patients Genotype 1 With Insulin Resistance and to Assess Prolonged Treatment Duration in Late Virological Responders.

Trial Profile

Study to Evaluate Response Rates in CHC [chronic hepatitis C] Patients Genotype 1 With Insulin Resistance and to Assess Prolonged Treatment Duration in Late Virological Responders.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 08 Feb 2011 Planned end date changed from 1 Jun 2011 to 1 Oct 2009 as reported by ClinicalTrials.gov.
    • 15 Dec 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 20 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top